personalized-medicine
(4)
Mylene Yao
Mylene Yao is co-founder, director, and CEO of Univfy, a Los Altos-based healthcare AI company that builds personalized IVF success prediction models. A board-certified OB/GYN trained at the University of Toronto, McGill, and Harvard, she was a Stanford faculty member running an NIH-funded embryo development lab before spinning her prediction research out with statistician Wing H. Wong. Univfy's models tell patients their individual odds of having a baby with IVF, and pair the prediction with financing so more people can actually pursue treatment.
Aihua Fu
Aihua Fu is a nanobiotechnologist and the co-founder, President and CEO of NVIGEN Inc., a San Jose nanobiotechnology company building molecularly engineered magnetic and fluorescent nanoparticles for cancer detection and personalized medicine. Trained as a chemist under Nobel-track nanoscience pioneer A. Paul Alivisatos at UC Berkeley and as a postdoc at Stanford, she turned quantum-dot and magnetic-bead research into commercial tools for liquid biopsy, cfDNA extraction, single-cell sequencing and circulating tumor cell capture. Her flagship NVIGEN X and NERNST-Seq platforms aim to read DNA, RNA, protein and cell signals together to predict cancer recurrence early and guide therapy.
Bob Wassman
Dr. E. Robert (Bob) Wassman is Chief Medical Officer and Executive Vice President of Clinical Development at MARAbio, a Utah-based diagnostics company building a maternal blood test to identify an autoimmune subtype of autism. A board-certified pediatrician and medical geneticist with more than 40 years in the field, he has served as chief medical officer for a long roster of genetic-testing pioneers including Genzyme Genetics, Ambry Genetics, Rosetta Genomics and Good Start Genetics, repeatedly turning frontier laboratory technology into clinical service across reproductive medicine, cancer, and neurodevelopmental disability.
Fred Parietti
Fred Parietti (Federico) is the Co-Founder and CEO of Multiply Labs, a San Francisco-based robotics company building automated biomanufacturing infrastructure for next-generation pharmaceuticals. Armed with a PhD in robotics from MIT and a childhood passion for Legos, he bet his career on a contrarian thesis: that the highest-value application for advanced robotics wasn't pizza delivery or self-driving cars, but cell therapy manufacturing — where a single batch is worth $400K to $2 million and still made by hand. Multiply Labs has raised over $25 million and announced an $85 million partnership with Retro Biosciences, positioning itself to slash cell therapy costs by 70% and bring life-saving treatments to millions instead of thousands.